Bendamustine

Bendamustine
Clinical data
Trade namesTreanda, others
Other namesSDX-105
AHFS/Drugs.comMonograph
MedlinePlusa608034
License data
Routes of
administration		Intravenous infusion
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNA (intravenous only)
Protein binding94–96%
MetabolismHydrolyzed to inactive metabolites. Two minor metabolites (M3 and M4) formed by CYP1A2
Elimination half-life40 min (bendamustine), 3 h (M3), 30 min (M4)
Excretion~50% urinary, ~25% fecal [2]
Identifiers
  • 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.205.789 Edit this at Wikidata
Chemical and physical data
FormulaC16H21Cl2N3O2
Molar mass358.26 g·mol−1
3D model (JSmol)
  • ClCCN(c2ccc1c(nc(n1C)CCCC(=O)O)c2)CCCl
  • InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23) checkY
  • Key:YTKUWDBFDASYHO-UHFFFAOYSA-N checkY
  (verify)

Bendamustine, sold under the brand name Treanda among others, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin's lymphoma.[3][4] It is given by injection into a vein.[3]

Common side effects include low blood cell counts, fever, nausea, diarrhea, loss of appetite, cough, and rash.[3] Other severe side effects include allergic reactions and increased risk of infection.[3] Use in pregnancy is known to harm the baby.[3] Bendamustine is in the alkylating agents family of medication.[3] It works by interfering with the function of DNA and RNA.[3]

Bendamustine was approved for medical use in the United States in 2008.[3] It is on the World Health Organization's List of Essential Medicines.[5][6] It was originally made from nitrogen mustard.[3]

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
  2. ^ Dubbelman AC, Rosing H, Darwish M, D'Andrea D, Bond M, Hellriegel E, et al. (March 2013). "Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy". Drugs in R&D. 13 (1): 17–28. doi:10.1007/s40268-012-0001-5. PMC 3627029. PMID 23322528.
  3. ^ a b c d e f g h i "Bendamustine Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  4. ^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 579. ISBN 9780857111562.
  5. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.